TABLE 1.
Characteristics of patients with haematological malignancies according to fungal infection status (n=84).
| Fungal Infection | |||
|---|---|---|---|
| Characteristicsa | YES | NO | P–valueb |
| n = 59 | n =25 | ||
| n (%) | n (%) | ||
|
|
|||
| Sex | 0·78c | ||
| Woman | 24 (68·6) | 11 (31·4) | |
| Men | 35 (71·4) | 14 (28·6) | |
| Age (in years) | 0·38 | ||
| 21–34 | 12 (80·0) | 3 (20·0) | |
| 35–54 | 19 (61·3) | 12 (38·7) | |
| 55–70 | 19 (67·9) | 9 (32·1) | |
| >70 | 8 (88·9) | 1 (11·1) | |
| Living environment | 0·32c | ||
| Urban | 26 (65·0) | 14 (35·0) | |
| Rural | 33 (75·0) | 11 (25·0) | |
| Comorbid conditions | |||
| Diabetes Mellitus | 18 (66·7) | 9 (33·3) | 0·70c |
| Hypertension/CAD | 31 (72·1) | 12 (27·9) | 0·60c |
| Bronchial Asthma | 3 (75·0) | 1 (25·0) | >0·99 |
| Thyroid Dysfunction | 7(100·0) | 0 (0·0) | 0·10 |
| HIV | 2 (66·7) | 1 (33·3) | >0·99 |
| Chronic kidney Diseased | 6 (85·7) | 1 (14·3) | 0·43 |
| Chronic Liver Disease | 2 (66·7) | 1 (33·3) | >0·99 |
| Survival | 0·61c | ||
| Dead | 22 (73·3) | 8 (26·7) | |
| Alive | 36 (63·9) | 17 (32·1) | |
| Hematologic Malignancy | 0·99c | ||
| Newly Diagnosed | 39 (69.6) | 17 (30.4) | |
| Reoccurrence | 16 (69.6) | 7 (30.4) | |
| Principal Dx | |||
| Acute Myeloid Leukemia | 32 (62·7) | 19 (37·3) | 0·07c |
| Chronic Myeloid Leukemia | 4 (100·0) | 0 (0·0) | 0·23e |
| Acute Lymphoid Leukemia | 14 (77·8) | 4 (22·2) | 0·56c |
| Non-Hodgkin Lymphoma | 4 (80·0) | 1 (20·0) | 0·52e |
| Hodgkin Lymphoma | 1 (50·0) | 1 (50·0) | 0·51e |
| Bone Marrow results at day 14 | >0·99 | ||
| Mean ± SD | 2·5 ± 1·1 | 2·5 ± 1·1 | |
| Bone Marrow Iron Stores | >0·99 | ||
| Decreased/Few bits | 2 (50·0) | 2 (50·0) | |
| Adequate | 3 (42·9) | 4 (57·1) | |
| Increased/Markedly Increased | 5 (50·0) | 5 (50·0) | |
| Acute Renal Failure | 25 (64·1) | 14 (35·9) | 0·25c |
| Sepsis during hospitalization | 43 (68·25) | 20 (31·75) | >0·99 |
| Broad Spectrum Antibiotics | 57 (70·4) | 24 (29·6) | 0·31e |
| Renal Replacement Therapy | 5 (62·5) | 3 (37·5) | 0·70 |
| Total Parenteral Nutrition | 10 (83·3) | 2 (16·7) | 0·20 |
| Use of steroids before dx | 32 (84·2) | 6 (15·8) | 0·02c |
| Surgery | 13 (86·7) | 2 (13·3) | 0·12 |
| Days on ventilation | 0·86 | ||
| 0 days | 29 (65·9) | 15 (34·1) | |
| 1 – 10 days | 9 (75·0) | 3 (25·0) | |
| >10 days | 7 (63·6) | 4 (36·4) | |
| Antifungal Medications | 0·07 | ||
| Azoles | 16 (88·9) | 2 (11·1) | |
| Echinocandins | 8 (100·0) | 0 (0·0) | |
| Amphotericin B | 7 (70·0) | 3 (30·0) | |
| Combination or different classes | 21 (63·6) | 12 (36·4) | |
| Intravenous Access | 0·11e | ||
| Central | 39 (73·6) | 14 (26·4) | |
| Peripheral | 6 (50·0) | 6 (50·0) | |
| Bacterial Organism | |||
| Gram positive cocci (not MRSA) | 23 (74·2) | 8 (25·8) | 0·59c |
| MRSA | 3 (100·0) | 0 (0·0) | 0·56 |
| Gram negative bacilli (not MDR) | 9 (69·2) | 4 (30·8) | >0·99 |
| Gram negative bacilli MDR | 12 (60·0) | 8 (40·0) | 0·21c |
| S. maltophilia | 3 (50·0) | 3 (50·0) | 0·35 |
| Bacterial Site | |||
| Lung | 7 (70·0) | 3 (30·0) | >0·99 |
| Bloodborne | 28 (75·7) | 9 (24·3) | 0·36c |
| Skin/Soft Tissue | 7 (63·6) | 4 (36·4) | 0·72 |
| Urinary Tract | 11 (68·7) | 5 (31·3) | >0·99c |
Abbreviations: MRSA, Methicillin resistant staphylococcus aureus; MDR, Multi drug resistant.
a
Total may not equal the overall sample size except for the following characteristics: sex, living environment, comorbid conditions, and acute renal failure;
b
Two-sided Fisher’s Exact test or Student’s T test was performed, as appropriate, unless otherwise specified;
c
Chi-square test was performed;
d
With or without haemodialysis;
e
One-sided Fisher’s Exact test was performed.